ALFA Filings
Every announcement, straight from the exchange
Every Aurobindo Pharma other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements
Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.
Aurobindo Pharma dispatched letters to shareholders without registered email IDs. These letters provide a web link to the Integrated Annual Report 2025-26.
Aurobindo Pharma appointed M/s. RPR & Associates as Secretarial Auditor for five years following M/s. MRR & Associates' resignation. The transition is due to proprietor health issues.
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, announced positive Phase 3 results for its Omalizumab biosimilar (BP11). The study met all primary endpoints for efficacy and safety, showing equivalence to Xolair. The company plans to file for EMA and FDA regulatory approvals by the end of Q2 2026.